Skip to main content
NYXH logo

Nyxoah S.A. (NYXH) Stock: Price, Forecast & Analyst Target

Nyxoah S.A. (NYXH) — MoonshotScore 17/100 (Weak band), calculated Nov 18, 2026. Price $0.8587 (-0.50%), as of the Nov 19, 2026 trading session; market cap $87.5M.

Educational signal · not a buy or sell recommendation · How to read this

$0.8587 −$0.0043 (-0.50%) Market Cap $87.5M

Nyxoah S.A. · NYXH · NASDAQ

Nyxoah S.A. is a medical technology company focused on developing and commercializing solutions for sleep-disordered breathing conditions. Its primary product is the CE-Marked Genio system, a hypoglossal neurostimulation therapy for moderate to severe obstructive sleep apnea.

Price as of Nov 19, 2026

Key Statistics

17 of 100

MoonshotScore v2 · Nyxoah (NYXH)

Weak
Business Quality Poor (15)
Financial Safety Fragile (17)
Valuation Bubble (6)
Growth Durability Flat (41)
Momentum Slipping (22)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a fragile balance sheet and an expensive valuation, though growth is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Flat; Momentum: Slipping.

  • quarterly revenue €2M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 2 of the last 8 reports
  • Altman Z -3.89 · Piotroski F 4

Holding back: weak fundamentals, balance-sheet strain, a rich price, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for NYXH (52 recorded, newest six shown)
RecordedScoreBand
17Weak
17Weak
17Weak
17Weak
17Weak
17Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.8587
Change on the day-0.50%
52-week range$0.80 – $5.39
Market capitalisation$87.5M—
Price / earnings (trailing)-1.38
Shares traded on the day87.4K

Price & events

Other perspectives

Council score for Nyxoah (NYXH): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Negative
Financial Safety Negative
Valuation Negative
Growth Durability Neutral
Momentum Weak

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Weak
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Nyxoah (NYXH), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Nyxoah S.A. (NYXH) is listed on NASDAQ. It employs 154 people and is led by Liam J. Kelly. In Q3 FY2025 it reported revenue of €2M and net income of -€24M. The market values it at $87.5M.

2 · Latest results

What do the latest results show for Nyxoah (NYXH)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of €2M. Against analyst estimates the company has EPS beat 2 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025€2M-€24M-€0.63 (diluted)
Q4 FY2025€6M-€24M-€0.59 (diluted)
Q1 FY2026€6M-€16M-€0.37 (diluted)
Q2 FY2026€8M-€33M-€0.58 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Nyxoah (NYXH)?

Short answer · as of

What is holding it back is weak fundamentals, balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Altman Z -3.89 · Piotroski F 4. Trailing ratios: ROA -62.3% · current ratio 2.19 · earnings yield -113.5% · free-cash-flow yield -90.5%.

Data-derived red flags

  • Listing risk — at $0.8587 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -3.89 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
4 · What to check next?

What should you watch next at Nyxoah (NYXH)?

Short answer · as of

Current published price targets run low $2.31 · high $4.00 · consensus $3.08 · median $3.00 against a quoted price of $0.8587 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • The newest quarter held here (Q3 FY2025) was filed Nov 13, 2025 — 11 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Nyxoah compare with its peers?

Short answer

Nyxoah's score ranks 4th of 4 in the bounded comparison shown, against 3 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Inspira Technologies Oxy B.H.N. Ltd. (QTEX) Same industry, near in market value$1.12 Nov 19, 2026$75.1M45 5-pillar Nov 18, 2026
SHOULDER INNOVATIONS, INC. (SI) Same industry, near in market value$20.65 Nov 18, 2026$432M34 5-pillar Nov 18, 2026
iTonic Holdings Ltd. (ITOC) Same industry, near in market value$1.50 Nov 19, 2026$11.0M29 5-pillar Nov 18, 2026
Nyxoah (NYXH) — this page$0.8587$87.5M17

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$2.31 – $4.00
Consensus target
$3.08
Median target
$3.00

Consensus record · Captured .

Measured against a quoted price of $0.8587 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held NYXH in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported NYXH in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Nyxoah (NYXH)?

Read these with our analysis →

What Investors Ask About Nyxoah (NYXH)

These answers are editorial: 1 of these 9 answers is drawn from the NYXH research dossier (written Jun 13, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for NYXH?

NYXH carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Nyxoah S.A. is a medical technology company focused on developing and commercializing solutions for sleep-disordered breathing conditions.

Is NYXH a good stock to buy?

Stock Expert AI does not rate NYXH buy, sell or hold. Nyxoah S.A. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the NYXH stock price today?

The last price recorded for Nyxoah S.A. (NYXH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the NYXH price target?

The analyst consensus price target for Nyxoah S.A. (NYXH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What does Nyxoah S.A. do?

Nyxoah S.A. is a medical technology company specializing in the development and commercialization of innovative solutions for sleep-disordered breathing conditions.

What are the key factors to evaluate for NYXH?

Nyxoah S.A. (NYXH) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Market Penetration and Adoption of the Genio System: Nyxoah's primary growth opportunity lies in expanding the market penetration and adoption of its CE-Marked Genio system within existing European markets. Not financial advice.

How frequently does NYXH data refresh on this page?

NYXH's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven NYXH's recent stock price performance?

Nyxoah S.A. (NYXH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: CE-Marked Genio system, validating its safety and efficacy in European markets. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider NYXH overvalued or undervalued right now?

Nyxoah S.A. (NYXH) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 20 figures on this page — 12 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.